Trustpilot Reviews

Geotrichum - Everything You Need to Know

Updated 10/14/2021

Written by Molecular Biologist Dr. Vibhuti Rana, PhD

The Geotrichum fungi was discovered in 1809. Microscopically, Geotrichum species produce hyaline, septate hyphae which show division into two parts or branches (dichotomous branching). They can be found in various places like soil, water, sewage, air, plants, dairy products and cereals (1). It has around 100 species included in it but the most relevant species are: Geotrichum candidum, Geotrichum clavatum, and Geotrichum capitatum (2).


Geotrichum strains grow rapidly at 25°C and produce white, dry, powdery to cottony colonies. They either don’t grow or grow very slowly at 37°C. The infection caused by Geotrichum spp. are referred to as geotrichosis and mainly attacks people with weak immune systems, known as immunocompromised hosts (3). The infection is caused mainly by inhalation or ingestion. Bronchial, pulmonary, disseminated infection and fungemia are some of the reported problems caused by Geotrichum (4).

Apart from causing infection in humans, recent reports points towards it role in environmental damage. It has been claimed recently that aluminum and data storing polycarbonate resins found in compact discs have been damaged by their growth on them. It caused disc coloration and increase in its transparency (5).

The Three Main Geotrichum Pathogenic Species

Geotrichum Candidum:

Geotrichum Candidum occurs mainly on human skin, sputum, and feces. Initially it was isolated from soil samples found across the globe. Usually they grow in temperature range of 25°C to 38°C (In plants it ranges from 25°C to 27°C and in animals 30°C to 31°C). Furthermore, a pH range of 5-5.0 is well tolerated by them (6). It has various important biochemical activities like protein degradation, enzyme production, catabolism of free fatty acids, and deacidification (7).

Production of enzyme varies from strain to strain and can be attributed to strain origin. Due to these properties, it is used in cheese production, where the release of protein enzymes like lipases and proteases give cheese its distinctive flavor. It is involved in the development of various cheese varieties like soft cheese from cow’s milk, goat’s milk, and ewe’s milk. Depending on the type of cheese being made, G. candidum can be used either at the start or throughout the entire process of ripening. However, overgrowth of G. candidum should be checked because it can lead to slippery rind effect and off flavor in cheese (8).

Apart from cheese making, it catabolizes lactic acid in Nordic yogurt and gives it the desired velvety texture. Till date, no foodborne disease has been linked to the consumption of products containing G. candidum. However, clinical significance in humans should not be neglected, as it can cause local or disseminated disease referred to as geotrichosis (9). The primary risk factor for geotrichosis is being immunocompromised, namely neutropenia, followed by hematological malignancy, HIV, diabetes mellitus, altered gut mucosal immunity, indwelling catheters, parenteral nutrition, prolonged use of broad-spectrum antibiotics, alcohol abuse, chronic lung or kidney disease. Other critical illnesses have also been implicated as risk factors.

The current recommended treatments for geotrichosis include amphotericin B with or without flucytosine or voriconazole alone (4). Moreover, therapy and outcome of Geotrichum infections are dependent on the degree of invasion of the organism and the status of the host. Thus, Geotrichum spp. are rare emerging fungi which, despite adequate antifungal therapy, are associated with a mortality rate approaching 50%. Clinicians should be more aware of geotrichosis as a clinical entity in immunocompromised and other patients.

Geotrichum Clavatum:

Geotrichum Clavatum also known as Saprochaete clavata, belongs to the genus Geotrichum. It has very rarely been associated with any kind of invasive human infection. Usually Aspergillus and Candida are fungi that cause major fungal infection leading to mortality amongst immunocompromised patients (10).

However, an outbreak of invasive infection by G. clavatum has recently been reported in hematological patients. The first case of G. clavatum infection was observed in Italy where three patients were reported in 2014. Two patients had acute myeloid leukemia and one patient had mantle cell lymphoma. Infection was diagnosed by positive blood cultures, which were further grown on chocolate agar and Sabouraud dextrose agar. The confirmatory test was done using MALDI-TOF mass spectrometry technique that could identify all the three isolates of G. clavatum. The average time taken by G. clavatum to grow on blood culture was 4 to 24 hours.

Infections by G. capitatum and G. clavatum show similar risk factors and clinical pictures. The former can be differentiated from G. candidum by the formation of annelloconidia, the ability to grow at 45 °C and resistance to cycloheximide (11).

While galactomannan and (1-3)-β-d-glucan positivity has been reported in the setting of G. capitatum infection, there is no literature to support the use of these tests to detect G. candidum. Advanced proteomic and genomic techniques like mass spectrometry and sequence analysis, can be used to characterize different strains within the same species (12).

Thus, G. clavatum seems to be an emerging, opportunistic agent in immunocompromised patients with malignant hematological disease. Further research is needed to determine the best antifungal strategy, the optimal duration of treatment, and to identify the reservoir of this species, the incubation period, and mode of transmission.

Geotrichum capitatum:

In recent years, the incidence rate of invasive fungal infection increased significantly, which has become one of the main causes of death for patients with hematologic malignancies. However, the rate of infection caused by Geotrichum capitatum is low, but with appearance of unusual clinical signs and symptoms in patients, makes its diagnosis difficult. It has low virulence, and it is considered as an opportunistic pathogen and can occur in patients with non-neutropenia and local infection (13).

G. capitatum infection occurs mainly in patients with hematologic malignancies, and long-time neutropenia, glucocorticoid treatment, deep venous catheterization, chemotherapy and the use of broad-spectrum antibiotics are all risk factors of fungal infection, including G. capitatum infection (14). 

It has been observed, climatic factors seem to play a selective role in the epidemiology of infections caused by Geotrichum capitatum, like 87 % are observed in Europe, 10 % in USA and 5 % in Asia (15).

Typically, G. capitatum infection is diagnosed using blood culture test, which is further confirmed by sputum culture test. The positive rate of blood culture varies from different fungi, like the positive rate of blood culture test is up to 70% in patients infected by G. capitatum, while that of Candida is less than 50%, Aspergillus is less than 10%, and Fusarium is roughly 56% (14). Apart from blood culture test, GM-ELISA, G test and CT scans can help with the diagnosis of infection.

Till date, no effective treatment has been established for G. capitatum infection. Using amphotericin B liposome or amphotericin B combined with voriconazole or other new antifungal agents may achieve a certain effect (16).

Since in many cases, G. capitatum infection is associated with poor prognosis, early diagnoses and early treatment with effective anti-fungal therapy might help the patient come out of agranulocytosis earlier and reduce death. Therefore, early anti-fungal treatment is a key factor in reducing mortality.

Treatment Options for Geotrichum Infections

Very limited antifungal agents have been tested in vitro for treatment of infections caused by Geotrichum. However, amongst the azoles, voriconazole, ketoconazole, and itraconazole have been tested. It was observed that out of three azoles, voriconazole yields the lowest minimum inhibitory concentration (MIC) followed by ketoconazole and itraconazole (17). In simple terms, a drug that works at the lowest MIC is the better one, since minimal doses are required.


Different species of Geotrichum are potentially pathogenic in immunocompromised hosts. The incidences caused by them might be underreported, since they can be misdiagnosed histo-pathologically as Candida spp., Aspergillus spp., or Trichosporon spp. in a few cases. Thus, this possibility for misdiagnosis illustrates the importance of obtaining fungal cultures in addition to histopathological data. Some of the key points which need to be considered are better awareness of their pathogenicity could delineate its true incidence, patterns of clinical disease, and responsiveness to therapy.

As always, it is best to work with your doctor for a correct diagnosis and when treating yourself for Geotrichum.

Back to Yeast Species

Dr. Rana's Medical References

1. Martin O'Brien, Padraig O'Kiely, Patrick D. Forristal, Hubert T. 1. Fuller, Fungi isolated from contaminated baled grass silage on farms in the Irish Midlands, FEMS Microbiology Letters, Volume 247, Issue 2, June 2005, Pages 131–135.
2. Guého E, de Hoog GS, Smith MT, Meyer SA. DNA relatedness, taxonomy, and medical significance of Geotrichum capitatum. J Clin Microbiol. 1987 Jul;25(7):1191-4.
3. Ng KP, Soo-Hoo TS, Koh MT, Kwan PW. Disseminated Geotrichum infection. Med J Malaysia. 1994 Dec;49(4):424-6. PMID: 7674982.
4. André N, Coze C, Gentet JC, Perez R, Bernard JL. Geotrichum candidum septicemia in a child with hepatoblastoma. Pediatr Infect Dis J. 2004 Jan;23(1):86.
5. Garcia-Guinea J, Cárdenes V, Martínez AT, Martínez MJ. Fungal bioturbation paths in a compact disk. Naturwissenschaften. 2001 Aug;88(8):351-4. doi: 10.1007/s001140100249.
6. Alper I, Frenette M, Labrie S. Ribosomal DNA polymorphisms in the yeast Geotrichum candidum. Fungal Biol. 2011 Dec; 115(12):1259-69.
7. Batt CA, Robinson RK. Encyclopedia of Food Microbiology. Elsevier Science; 2014
8. Boutrou R, Guéguen M. Interests in Geotrichum candidum for cheese technology. Int J Food Microbiol. 2005 Jun 25;102(1):1-20.
9. Leclercq-Perlat MN, Buono F, Lambert D, et al. Controlled production of Camembert-type cheeses. Part I: Microbiological and physicochemical evolutions. The Journal of Dairy Research. 2004 Aug;71(3):346-354.
10. Martino R, Salavert M, Parody R, Tomás JF, de la Cámara R, Vázquez L, Jarque I, Prieto E, Sastre JL, Gadea I, Pemán J, Sierra J. Blastoschizomyces capitatus infection in patients with leukemia: report of 26 cases. Clin Infect Dis. 2004 Feb 1;38(3):335-41.
11. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002 Apr 1;34(7):909-17.
12. Polacheck I, Salkin IF, Kitzes-Cohen R, Raz R. Endocarditis caused by Blastoschizomyces capitatus and taxonomic review of the genus. J Clin Microbiol. 1992 Sep;30(9):2318-22.
13. Gao GX, Tang HL, Zhang X, Xin XL, Feng J, Chen XQ. Invasive fungal infection caused by geotrichum capitatum in patients with acute lymphoblastic leukemia: a case study and literature review. Int J Clin Exp Med. 2015 Aug 15;8(8):14228-35.
14. Alper I, Frenette M, Labrie S. Ribosomal DNA polymorphisms in the yeast Geotrichum candidum. Fungal Biol. 2011 Dec;115(12):1259-69.
15. Özkaya-Parlakay A, Cengiz AB, Karadağ-Öncel E, Kuşkonmaz B, Sarıbaş Z, Kara A, Oğuz B. Geotrichum capitatum septicemia in a hematological malignancy patient with positive galactomannan antigen: case report and review of the literature. Turk J Pediatr. 2012 Nov-Dec;54(6):674-8.
16. Girmania C, Pagano L, Martino B, D’Antonio D, Fanci R, Specchia G, et al. Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with haematological malignancies: a retrospective multicenter study from Italy and review of the literature. J Clin Microbiol. 2005;43:1818–28
17. Etienne A, Datry A, Gaspar N, Morel V, Delabesse E, Lmimouni B, Vernant JP, Dhédin N. Successful treatment of disseminated Geotrichum capitatum infection with a combination of caspofungin and voriconazole in an immunocompromised patient. Mycoses. 2008 May;51(3):270-2.

Home   Privacy Policy   Copyright Policy   Disclosure Policy   Doctors   Store

Copyright © 2003 - 2024. All Rights Reserved under USC Title 17. Do not copy
content from the pages of this website without our expressed written consent.
To do so is Plagiarism, Not Fair Use, is Illegal, and a violation of the
The Digital Millennium Copyright Act of 1998.